The GLP-1 Agonist Boom in ME/CFS, FM and Long COVID: Insights, Using it, Trials Underway by Cort Johnson | Nov 3, 2025 | COVID-19, Dempsey, Epstein-Barr Virus, GLP-1, Gut, Homepage, Immune, Inflammation, Kaufman, Mast cell activation syndrome, Mast cell activation syndrome, Neuroinflammation, Pathogens, POTS, RECOVER Initiative, Severe ME/CFS, Treatment Complex, chronic illness experts discuss what GLP-1 agonists can and can't do in diseases like ME/CFS, long COVID, and POTS
It's sterile water with a tiny amount of preservative that keeps the mixed solution safe to use over multiple doses
Time in on without dyskinesia is expressed as a percentage and represents the time in the on state without dyskinesia (the highest being the best)
I did not expect much from this product due to the popularity of the GLP-1. I thought there was no way it would be the same thing
Poole, Leslie B
Gastrointestinal symptomsnausea, vomiting, diarrhea, and decreased appetiteoccur most frequently, particularly during dose escalation
